Reuters logo
9 个月前
BRIEF-Daiichi Sankyo begins enrollment for late-stage trial testing Quizartinib in leukemia patients
2016年10月11日 / 中午12点17分 / 9 个月前

BRIEF-Daiichi Sankyo begins enrollment for late-stage trial testing Quizartinib in leukemia patients

1 分钟阅读

Oct 11 (Reuters) - Daiichi Sankyo Co Ltd:

* Daiichi Sankyo Co Ltd - first patient has been enrolled in global phase 3 quantum-first study evaluating oral FLT3-ITD inhibitor quizartinib

* Daiichi Sankyo Co Ltd - looking to combine quizartinib with other investigational agents in Co's pipeline such as MDM2 and BRD4 inhibitors Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below